Skip to main content
. 2020 Nov 3;11(44):4045–4073. doi: 10.18632/oncotarget.27785

Figure 3. Illustration of chimeric antigen receptor T-cell (CAR-T) immunotherapy approach.

Figure 3

CAR-T immunotherapy approach allows the use of the patient’s T-cells to attack cancer cells. CAR-T immunotherapy requires collecting patient’s immune cells and modifying them to express specific CARs that recognize specific cancer antigens by transfecting T- cells with viral vectors. Once T cells are successfully engineered to express the antigen-specific CAR, they are expanded and then re-administered into the patient to recognize and kill cancer cells.